L & S Advisors Inc reduced its position in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 33.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,390 shares of the medical research company’s stock after selling 6,635 shares during the period. L & S Advisors Inc’s holdings in Accelerate Diagnostics were worth $301,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AXDX. Schwab Charles Investment Management Inc. grew its holdings in Accelerate Diagnostics by 7.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,236 shares of the medical research company’s stock worth $3,207,000 after acquiring an additional 7,930 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Accelerate Diagnostics by 13.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock valued at $578,000 after purchasing an additional 2,425 shares during the last quarter. Artemis Investment Management LLP bought a new position in shares of Accelerate Diagnostics in the 3rd quarter valued at about $2,245,000. Wells Fargo & Company MN boosted its stake in shares of Accelerate Diagnostics by 21.2% in the 2nd quarter. Wells Fargo & Company MN now owns 73,328 shares of the medical research company’s stock valued at $2,005,000 after purchasing an additional 12,840 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Accelerate Diagnostics by 51.0% in the 1st quarter. Bank of America Corp DE now owns 15,200 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 5,132 shares during the last quarter. 47.98% of the stock is owned by institutional investors and hedge funds.

In other Accelerate Diagnostics news, Director Jack W. Schuler bought 50,000 shares of Accelerate Diagnostics stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $18.46 per share, with a total value of $923,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack W. Schuler bought 276,200 shares of Accelerate Diagnostics stock in a transaction dated Thursday, October 12th. The stock was acquired at an average cost of $19.74 per share, with a total value of $5,452,188.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 981,667 shares of company stock worth $18,879,924. 50.00% of the stock is owned by corporate insiders.

Accelerate Diagnostics Inc (NASDAQ AXDX) opened at $28.20 on Friday. Accelerate Diagnostics Inc has a fifty-two week low of $16.75 and a fifty-two week high of $30.45.

Several research analysts recently weighed in on the stock. ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $33.00.

TRADEMARK VIOLATION NOTICE: “Accelerate Diagnostics Inc (AXDX) Position Lessened by L & S Advisors Inc” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2017/12/08/accelerate-diagnostics-inc-axdx-position-lessened-by-l-s-advisors-inc.html.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.